agilon health (AGL) Financials

$2.22 +0.03 (+1.14%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$2.22 -0.01 (-0.45%)

As of 05/23/2025 06:21 PM Eastern

Annual Income Statements for agilon health

This table shows agilon health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Income / (Loss) Attributable to Common Shareholders	-260	-263	-107	-406	-60	-283
Consolidated Net Income / (Loss)	-260	-263	-107	-407	-60	-283
Net Income / (Loss) Continuing Operations	-250	-195	-92	-384	-63	-114
Total Pre-Tax Income	-249	-194	-91	-383	-62	-115
Total Operating Income	-292	-232	-105	-372	-57	-107
Total Gross Profit	4.84	4,316	111	66	1,218	794
Total Revenue	6,061	4,316	2,388	1,521	1,218	794
Operating Revenue	6,061	4,316	2,388	1,521	1,218	794
Total Cost of Revenue	6,056	0.00	2,277	1,456	0.00	0.00
Operating Cost of Revenue	6,056	-	2,277	1,456	-	-
Total Operating Expenses	297	4,548	217	438	1,275	901
Selling, General & Admin Expense	269	286	208	428	137	123
Depreciation Expense	24	16	8.95	10	14	12
Impairment Charge	3.60	0.00	0.00	-	-	-
Total Other Income / (Expense), net	43	38	15	-11	-5.67	-8.11
Interest Expense	6.18	6.66	4.48	6.15	8.14	9.07
Interest & Investment Income	15	16	11	-6.77	0.00	-
Other Income / (Expense), net	34	28	8.47	2.18	2.47	0.96
Income Tax Expense	1.45	0.79	1.64	0.89	0.87	-0.23
Net Income / (Loss) Discontinued Operations	-9.82	-68	-15	-23	3.16	-168
Net Income / (Loss) Attributable to Noncontrolling Interest	0.05	-0.21	-0.31	-0.30	0.00	-0.15
Weighted Average Basic Shares Outstanding	410.97M	408.92M	408.15M	372.93M	323.46M	294.74M
Weighted Average Diluted Shares Outstanding	410.97M	408.92M	408.15M	372.93M	323.46M	294.74M
Weighted Average Basic & Diluted Shares Outstanding	412.30M	409.54M	413.12M	372.93M	323.46M	294.74M

This table shows agilon health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	12	-106	-118	-31	-6.06	-230	-31	-17	16	-12	-31
Consolidated Net Income / (Loss)	12	-106	-118	-31	-6.03	-230	-31	-17	16	-57	-31
Net Income / (Loss) Continuing Operations	-1.89	-106	-116	-31	3.25	-167	-22	-16	9.95	-41	-31
Total Pre-Tax Income	-1.69	-105	-117	-30	3.11	-167	-21	-15	8.19	3.81	-30
Total Operating Income	-22	-108	-134	-43	-7.18	-164	-39	-29	0.42	-12	-30
Total Gross Profit	51	-1,568	-64	32	1,604	3,171	37	55	1,054	-585	26
Total Revenue	1,533	1,522	1,451	1,483	1,604	1,056	1,137	1,069	1,054	1,023	695
Operating Revenue	1,533	1,522	1,451	1,483	1,604	1,056	1,137	1,069	1,054	-	695
Total Cost of Revenue	1,482	3,090	1,515	1,451	0.00	-2,115	1,100	1,015	0.00	1,608	669
Operating Cost of Revenue	1,482	-	1,515	1,451	-	-	1,100	1,015	-	-	669
Total Operating Expenses	73	-1,459	69	76	1,612	3,335	76	84	1,054	-1,184	55
Selling, General & Admin Expense	66	60	63	70	76	65	72	79	70	64	52
Depreciation Expense	6.88	6.49	6.22	5.91	5.84	4.74	4.08	4.28	2.95	-0.92	3.45
Total Other Income / (Expense), net	20	3.43	16	13	10	-2.57	18	14	7.78	15	-0.43
Interest Expense	1.52	1.57	1.62	1.70	1.28	1.99	1.62	1.56	1.49	1.67	1.00
Interest & Investment Income	13	-2.69	2.05	9.96	5.68	-8.02	15	8.47	1.38	-	-4.31
Other Income / (Expense), net	9.26	7.70	16	4.84	5.89	7.44	5.42	7.09	7.89	-	4.89
Income Tax Expense	0.20	1.76	-0.59	0.42	-0.13	0.27	1.21	1.07	-1.76	0.57	0.56
Net Income / (Loss) Discontinued Operations	14	0.64	-1.18	0.00	-9.28	-63	-9.44	-0.77	6.01	-15	-0.24
Net Income / (Loss) Attributable to Noncontrolling Interest	0.00	-	0.00	0.02	0.03	-0.05	-0.05	-0.05	-0.06	-0.23	-0.07
Weighted Average Basic Shares Outstanding	412.94M	410.97M	411.59M	411.27M	408.94M	408.92M	405.79M	410.34M	413.14M	408.15M	411.07M
Weighted Average Diluted Shares Outstanding	412.94M	410.97M	411.59M	411.27M	413.44M	408.92M	405.79M	410.34M	426.59M	408.15M	411.07M
Weighted Average Basic & Diluted Shares Outstanding	413.95M	412.30M	412.02M	411.48M	411.26M	409.54M	406.04M	405.48M	414.83M	413.12M	411.85M

This table details how cash moves in and out of agilon health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Change in Cash & Equivalents	80	-393	-547	916	-6.52	67
Net Cash From Operating Activities	-58	-156	-131	-148	-53	-104
Net Cash From Continuing Operating Activities	-58	-156	-131	-148	-12	-104
Net Income / (Loss) Continuing Operations	-260	-263	-107	-407	-60	-283
Consolidated Net Income / (Loss)	-260	-263	-107	-407	-60	-283
Depreciation Expense	24	20	14	15	14	41
Non-Cash Adjustments To Reconcile Net Income	47	97	21	302	30	120
Changes in Operating Assets and Liabilities, net	131	-10	-59	-58	3.66	17
Net Cash From Investing Activities	140	-44	-444	-91	22	-5.06
Net Cash From Continuing Investing Activities	140	-44	-444	-91	22	-5.06
Purchase of Property, Plant & Equipment	-13	-16	-15	-6.56	-1.78	-2.89
Acquisitions	-28	-60	-17	-6.86	-0.58	-1.01
Purchase of Investments	-12	-115	-458	0.00	0.00	-
Divestitures	0.00	2.19	0.50	-1.34	26	0.00
Sale and/or Maturity of Investments	207	164	53	7.10	2.06	-
Other Investing Activities, net	-14	-20	-6.51	-83	-3.85	-1.15
Net Cash From Financing Activities	-2.58	-193	28	1,154	25	176
Net Cash From Continuing Financing Activities	-2.58	-193	28	1,154	25	176
Repayment of Debt	-3.75	-5.00	-5.00	-135	-3.04	-3.59
Repurchase of Common Equity	0.00	-200	0.00	0.00	-6.74	0.00
Issuance of Common Equity	1.17	12	33	1,189	34	180

This table details how cash moves in and out of agilon health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-55	40	37	-2.21	4.22	-64	-23	-203	-103	-57	-119
Net Cash From Operating Activities	-32	16	-7.70	-19	-48	-61	-13	-21	-61	-50	2.65
Net Cash From Continuing Operating Activities	-32	16	-7.70	-19	-48	-61	-13	-21	-61	-50	2.65
Net Income / (Loss) Continuing Operations	12	-106	-118	-31	-6.03	-230	-31	-17	16	-57	-31
Consolidated Net Income / (Loss)	12	-106	-118	-31	-6.03	-230	-31	-17	16	-57	-31
Depreciation Expense	6.88	6.49	6.22	5.91	5.84	5.15	5.31	5.52	4.19	3.91	3.45
Non-Cash Adjustments To Reconcile Net Income	-12	9.95	12	10	16	69	6.89	11	11	1.97	13
Changes in Operating Assets and Liabilities, net	-39	106	92	-3.98	-63	96	6.27	-20	-91	0.71	17
Net Cash From Investing Activities	-23	24	47	18	51	-2.20	-11	20	-51	-7.97	-131
Net Cash From Continuing Investing Activities	-23	24	47	18	51	-2.20	-11	20	-51	-7.97	-131
Purchase of Property, Plant & Equipment	-3.85	-3.27	-3.53	-3.31	-3.14	-3.93	-4.09	-4.09	-3.72	-3.49	-3.43
Acquisitions	-7.03	-9.16	-0.98	-6.46	-11	-12	-1.81	-1.84	-44	-4.82	-0.25
Purchase of Investments	-48	-	-	-12	0.00	-7.64	-41	-36	-30	-35	-138
Sale and/or Maturity of Investments	35	40	51	41	75	30	37	69	29	37	11
Other Investing Activities, net	0.00	-3.99	-	-1.23	-8.51	-11	-0.31	-7.17	-1.30	-2.00	-
Net Cash From Financing Activities	-0.16	-0.02	-1.41	-1.71	0.56	-0.85	1.41	-202	8.34	1.13	9.11
Net Cash From Continuing Financing Activities	-0.16	-0.02	-1.41	-1.71	0.56	-0.85	1.41	-202	8.34	1.13	9.11
Repayment of Debt	0.00	-	-1.25	-1.25	-1.25	-1.25	-1.25	-1.25	-1.25	-1.25	-1.25
Issuance of Common Equity	-0.16	-0.02	-0.16	-0.46	1.81	0.41	2.66	-0.79	9.59	2.38	10

This table presents agilon health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Total Assets	1,734	1,741	1,697	1,586	446
Total Current Assets	1,458	1,480	1,451	1,367	294
Cash & Equivalents	188	108	465	1,040	107
Restricted Cash	5.63	6.76	11	15	-
Short-Term Investments	212	381	412	0.00	-
Accounts Receivable	1,017	942	492	293	145
Prepaid Expenses	35	43	32	19	9.64
Plant, Property, & Equipment, net	28	28	20	9.16	6.46
Total Noncurrent Assets	248	233	226	210	146
Goodwill	24	24	2.51	42	42
Intangible Assets	73	64	18	55	60
Other Noncurrent Operating Assets	151	145	106	113	44
Total Liabilities & Shareholders' Equity	1,734	1,741	1,697	1,586	446
Total Liabilities	1,263	1,080	657	495	422
Total Current Liabilities	1,152	977	535	357	267
Accounts Payable	220	239	177	113	97
Other Current Liabilities	932	738	301	239	163
Total Noncurrent Liabilities	111	103	122	138	155
Long-Term Debt	35	32	38	43	65
Other Noncurrent Operating Liabilities	76	70	82	94	90
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	471	661	1,041	1,092	-285
Total Preferred & Common Equity	471	662	1,041	1,092	-285
Total Common Equity	471	662	1,041	1,092	-285
Common Stock	2,058	1,991	2,111	2,050	266
Retained Earnings	-1,587	-1,327	-1,064	-958	-551
Accumulated Other Comprehensive Income / (Loss)	-0.09	-2.30	-5.56	0.00	-
Noncontrolling Interest	0.00	-0.82	-0.61	-0.30	0.00

This table presents agilon health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,933	2,091	2,163	2,316	2,278	2,353	2,170	1,870
Total Current Assets	1,651	1,812	1,884	2,037	1,957	2,045	1,876	1,634
Cash & Equivalents	137	148	109	112	168	191	394	551
Restricted Cash	1.68	5.63	6.85	6.84	10	10	10	-
Short-Term Investments	230	245	292	307	396	389	422	408
Accounts Receivable	1,240	1,368	1,437	1,571	1,346	1,417	1,005	638
Prepaid Expenses	42	45	39	40	37	38	45	24
Plant, Property, & Equipment, net	28	28	28	28	26	24	22	18
Total Noncurrent Assets	254	251	251	252	295	284	272	218
Goodwill	24	24	24	24	62	62	62	42
Intangible Assets	68	73	75	72	93	94	93	61
Other Noncurrent Operating Assets	162	154	153	156	140	127	117	116
Total Liabilities & Shareholders' Equity	1,933	2,091	2,163	2,316	2,278	2,353	2,170	1,870
Total Liabilities	1,433	1,517	1,487	1,628	1,406	1,473	1,088	785
Total Current Liabilities	1,375	1,409	1,387	1,527	1,301	1,362	973	658
Short-Term Debt	35	-	8.75	7.50	5.00	5.00	5.00	5.00
Accounts Payable	227	218	281	252	291	258	222	162
Other Current Liabilities	1,113	1,191	1,098	1,267	1,006	1,100	746	491
Total Noncurrent Liabilities	58	107	100	101	105	111	116	127
Long-Term Debt	0.00	35	27	30	35	36	37	40
Other Noncurrent Operating Liabilities	58	72	73	71	70	75	79	87
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	500	575	676	688	872	879	1,082	1,085
Total Preferred & Common Equity	500	575	677	689	872	880	1,083	1,086
Total Common Equity	500	575	677	689	872	880	1,083	1,086
Common Stock	2,075	2,056	2,043	2,025	1,975	1,951	2,134	2,099
Retained Earnings	-1,575	-1,481	-1,364	-1,333	-1,096	-1,065	-1,048	-1,008
Accumulated Other Comprehensive Income / (Loss)	0.54	0.30	-2.45	-2.75	-6.23	-6.37	-3.55	-5.10

This table displays calculated financial ratios and metrics derived from agilon health's official financial filings.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Growth Metrics	-	-	-	-	-	-
Revenue Growth	40.41%	80.74%	56.97%	24.88%	53.36%	0.00%
EBITDA Growth	-26.64%	-121.49%	76.61%	-786.07%	37.53%	0.00%
EBIT Growth	-26.11%	-110.82%	73.81%	-582.67%	48.68%	0.00%
NOPAT Growth	-25.85%	-120.29%	71.69%	-556.82%	46.82%	0.00%
Net Income Growth	1.03%	-145.92%	73.73%	-577.39%	78.76%	0.00%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	63.01%	-19.41%	11.71%	-178.47%	48.77%	0.00%
Free Cash Flow Firm Growth	57.52%	-154.39%	72.71%	-1,392.04%	0.00%	0.00%
Invested Capital Growth	-49.42%	80.24%	29.12%	650.88%	0.00%	0.00%
Revenue Q/Q Growth	8.34%	0.77%	57.55%	-10.06%	0.00%	0.00%
EBITDA Q/Q Growth	19.86%	-204.28%	21.89%	2.40%	0.00%	0.00%
EBIT Q/Q Growth	17.97%	-157.18%	19.20%	2.33%	0.00%	0.00%
NOPAT Q/Q Growth	16.13%	-192.23%	12.14%	3.52%	0.00%	0.00%
Net Income Q/Q Growth	32.41%	-195.72%	0.18%	-8.69%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	57.32%	-7.73%	-0.82%	-31.58%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	9.78%	-13.03%	43.20%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-52.53%	-41.17%	-35.58%	4.94%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	0.08%	100.00%	4.66%	4.32%	100.00%	100.00%
EBITDA Margin	-3.85%	-4.27%	-3.48%	-23.36%	-3.29%	-8.08%
Operating Margin	-4.82%	-5.38%	-4.41%	-24.47%	-4.65%	-13.42%
EBIT Margin	-4.25%	-4.73%	-4.06%	-24.32%	-4.45%	-13.30%
Profit (Net Income) Margin	-4.29%	-6.09%	-4.47%	-26.74%	-4.93%	-35.59%
Tax Burden Percent	104.53%	135.14%	117.86%	106.22%	96.33%	246.53%
Interest Burden Percent	96.58%	95.19%	93.56%	103.49%	115.01%	108.59%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-137.02%	-105.45%	-75.60%	-747.53%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-123.67%	-91.05%	-72.18%	-719.59%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	91.06%	74.56%	65.57%	674.65%	0.00%	0.00%
Return on Equity (ROE)	-45.96%	-30.89%	-10.02%	-72.88%	-242.44%	0.00%
Cash Return on Invested Capital (CROIC)	-71.38%	-162.71%	-101.01%	-424.07%	0.00%	0.00%
Operating Return on Assets (OROA)	-14.83%	-11.88%	-5.90%	-36.41%	-12.14%	0.00%
Return on Assets (ROA)	-14.97%	-15.29%	-6.51%	-40.03%	-13.45%	0.00%
Return on Common Equity (ROCE)	-45.99%	-30.91%	-10.03%	-52.69%	2,786.82%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-55.23%	-39.71%	-10.26%	-37.26%	21.09%	0.00%
Net Operating Profit after Tax (NOPAT)	-204	-162	-74	-261	-40	-75
NOPAT Margin	-3.37%	-3.76%	-3.09%	-17.13%	-3.26%	-9.39%
Net Nonoperating Expense Percent (NNEP)	-13.34%	-14.40%	-3.42%	-27.94%	-101.32%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-40.42%	-23.44%	-6.80%	-	-	-
Cost of Revenue to Revenue	99.92%	0.00%	95.34%	95.68%	0.00%	0.00%
SG&A Expenses to Revenue	4.44%	6.62%	8.70%	28.10%	11.27%	15.46%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	4.90%	105.38%	9.08%	28.79%	104.65%	113.42%
Earnings before Interest and Taxes (EBIT)	-258	-204	-97	-370	-54	-106
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-233	-184	-83	-355	-40	-64
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	1.66	7.70	6.38	9.73	0.00	0.00
Price to Tangible Book Value (P/TBV)	2.09	8.88	6.52	10.68	0.00	0.00
Price to Revenue (P/Rev)	0.13	1.18	2.78	6.99	0.88	1.35
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	4.11	23.37	52.76	112.96	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.07	1.07	2.43	6.32	1.10	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.07	0.05	0.04	0.04	2.73	0.00
Long-Term Debt to Equity	0.07	0.05	0.04	0.04	2.61	0.00
Financial Leverage	-0.74	-0.82	-0.91	-0.94	-1.62	0.00
Leverage Ratio	3.07	2.02	1.54	1.82	18.02	0.00
Compound Leverage Factor	2.96	1.92	1.44	1.88	20.72	0.00
Debt to Total Capital	6.90%	4.66%	4.01%	4.25%	73.21%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.46%	0.44%	3.29%	0.00%
Long-Term Debt to Total Capital	6.90%	4.66%	3.55%	3.81%	69.93%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	-0.12%	-0.06%	-0.03%	334.68%	0.00%
Common Equity to Total Capital	93.10%	95.46%	96.05%	95.78%	-307.90%	0.00%
Debt to EBITDA	-0.15	-0.18	-0.52	-0.14	-1.69	0.00
Net Debt to EBITDA	1.59	2.51	10.16	2.83	0.97	0.00
Long-Term Debt to EBITDA	-0.15	-0.18	-0.46	-0.12	-1.61	0.00
Debt to NOPAT	-0.17	-0.20	-0.59	-0.19	-1.71	0.00
Net Debt to NOPAT	1.81	2.85	11.45	3.86	0.99	0.00
Long-Term Debt to NOPAT	-0.17	-0.20	-0.52	-0.17	-1.63	0.00
Altman Z-Score	2.31	4.20	7.06	13.00	2.20	0.00
Noncontrolling Interest Sharing Ratio	-0.07%	-0.08%	-0.04%	27.70%	1,249.50%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	1.27	1.51	2.71	3.83	1.10	0.00
Quick Ratio	1.23	1.46	2.56	3.74	0.94	0.00
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-107	-251	-99	-361	-24	0.00
Operating Cash Flow to CapEx	-436.02%	-986.73%	-847.97%	-2,257.15%	-2,997.41%	-3,591.32%
Free Cash Flow to Firm to Interest Expense	-17.25	-37.66	-21.98	-58.77	-2.98	0.00
Operating Cash Flow to Interest Expense	-9.35	-23.46	-29.17	-24.11	-6.54	-11.45
Operating Cash Flow Less CapEx to Interest Expense	-11.50	-25.84	-32.61	-25.17	-6.76	-11.77
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	3.49	2.51	1.45	1.50	2.73	0.00
Accounts Receivable Turnover	6.19	6.02	6.08	6.95	8.43	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	217.44	181.69	164.15	194.85	188.71	0.00
Accounts Payable Turnover	26.34	0.00	15.68	13.85	0.00	0.00
Days Sales Outstanding (DSO)	59.01	60.67	60.05	52.53	43.31	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	13.86	0.00	23.27	26.35	0.00	0.00
Cash Conversion Cycle (CCC)	45.15	60.67	36.77	26.18	43.31	0.00
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	100	198	110	85	-15	0.00
Invested Capital Turnover	40.61	28.01	24.48	43.65	-157.59	0.00
Increase / (Decrease) in Invested Capital	-98	88	25	101	-15	0.00
Enterprise Value (EV)	412	4,632	5,802	9,622	1,342	0.00
Market Capitalization	783	5,096	6,647	10,629	1,072	1,072
Book Value per Share	$1.14	$1.63	$2.53	$2.77	($0.88)	$0.00
Tangible Book Value per Share	$0.91	$1.41	$2.48	$2.53	($1.20)	$0.00
Total Capital	506	693	1,084	1,140	92	0.00
Total Debt	35	32	43	48	68	0.00
Total Long-Term Debt	35	32	38	43	65	0.00
Net Debt	-371	-463	-844	-1,006	-39	0.00
Capital Expenditures (CapEx)	13	16	15	6.56	1.78	2.89
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-100	7.82	33	-40	-76	0.00
Debt-free Net Working Capital (DFNWC)	306	503	921	1,015	30	0.00
Net Working Capital (NWC)	306	503	916	1,010	27	0.00
Net Nonoperating Expense (NNE)	56	100	33	146	20	208
Net Nonoperating Obligations (NNO)	-371	-463	-931	-1,006	-40	0.00
Total Depreciation and Amortization (D&A)	24	20	14	15	14	41
Debt-free, Cash-free Net Working Capital to Revenue	-1.65%	0.18%	1.40%	-2.60%	-6.27%	0.00%
Debt-free Net Working Capital to Revenue	5.05%	11.65%	38.57%	66.73%	2.50%	0.00%
Net Working Capital to Revenue	5.05%	11.65%	38.36%	66.40%	2.25%	0.00%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	410.97M	408.92M	408.15M	401.18M	0.00	0.00
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	410.97M	408.92M	408.15M	401.18M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	412.30M	409.54M	413.12M	372.93M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-202	-162	-74	-261	-40	-75
Normalized NOPAT Margin	-3.33%	-3.76%	-3.09%	-17.13%	-3.26%	-9.39%
Pre Tax Income Margin	-4.11%	-4.51%	-3.80%	-25.17%	-5.12%	-14.44%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	-41.71	-30.68	-21.61	-60.21	-6.66	-11.65
NOPAT to Interest Expense	-33.11	-24.41	-16.45	-42.40	-4.88	-8.23
EBIT Less CapEx to Interest Expense	-43.85	-33.06	-25.05	-61.28	-6.88	-11.97
NOPAT Less CapEx to Interest Expense	-35.25	-26.78	-19.89	-43.46	-5.09	-8.55
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-0.11%
Augmented Payout Ratio	0.00%	-76.10%	0.00%	0.00%	-11.23%	-0.11%

This table displays calculated financial ratios and metrics derived from agilon health's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-4.46%	44.16%	27.63%	38.69%	52.17%	3.21%	63.61%	59.54%	0.00%	578.44%	51.51%
EBITDA Growth	-231.04%	38.10%	-289.44%	-99.30%	-63.53%	-1,871.85%	-34.85%	-48.51%	131.38%	68.44%	33.67%
EBIT Growth	-899.14%	35.99%	-246.75%	-76.05%	-115.48%	-1,252.13%	-37.52%	-55.60%	119.23%	58.60%	31.34%
NOPAT Growth	-106.79%	34.21%	-239.77%	-49.68%	-1,577.59%	-1,066.50%	-33.12%	-37.55%	101.67%	46.17%	17.09%
Net Income Growth	300.73%	54.10%	-273.58%	-82.57%	-137.81%	-307.58%	-2.42%	18.99%	1,281.73%	0.33%	14.51%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	33.05%	126.84%	40.83%	11.73%	21.44%	-22.43%	-591.80%	64.81%	-161.74%	-2.17%	113.83%
Free Cash Flow Firm Growth	1,257.92%	110.97%	116.67%	97.58%	93.62%	-486.45%	-75.78%	-41.29%	9.18%	70.86%	-3.90%
Invested Capital Growth	-44.51%	-49.42%	-37.32%	-7.94%	0.91%	80.24%	97.37%	83.40%	117.10%	29.12%	110.34%
Revenue Q/Q Growth	0.68%	4.93%	-2.15%	-7.58%	64.17%	-7.11%	6.34%	1.40%	3.04%	47.26%	3.69%
EBITDA Q/Q Growth	93.64%	15.57%	-241.24%	-815.14%	103.20%	-431.19%	-74.63%	-230.86%	262.44%	63.67%	-92.32%
EBIT Q/Q Growth	87.20%	14.51%	-205.03%	-2,894.01%	99.13%	-363.11%	-54.87%	-363.21%	171.62%	52.90%	-75.24%
NOPAT Q/Q Growth	79.55%	19.03%	-208.02%	-305.38%	93.08%	-318.13%	-35.70%	-4,101.65%	105.14%	52.28%	-40.21%
Net Income Q/Q Growth	111.45%	10.05%	-283.59%	-408.15%	97.38%	-632.09%	-87.45%	-205.24%	128.22%	-83.97%	-48.28%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-294.82%	313.15%	58.84%	60.82%	21.89%	-369.86%	38.61%	65.13%	-21.72%	-1,987.38%	104.39%
Free Cash Flow Firm Q/Q Growth	429.29%	-30.97%	882.58%	59.50%	94.97%	-4.91%	-13.67%	-6.66%	-361.06%	68.55%	8.63%
Invested Capital Q/Q Growth	65.98%	-52.53%	-30.53%	1.37%	46.67%	-41.17%	2.04%	11.11%	170.24%	-35.58%	-5.19%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	3.31%	-102.96%	-4.42%	2.17%	100.00%	300.23%	3.24%	5.10%	100.00%	-57.14%	3.73%
EBITDA Margin	-0.39%	-6.17%	-7.67%	-2.20%	0.28%	-14.37%	-2.51%	-1.53%	1.19%	-0.75%	-3.05%
Operating Margin	-1.44%	-7.10%	-9.20%	-2.92%	-0.45%	-15.56%	-3.46%	-2.71%	0.04%	-1.13%	-4.25%
EBIT Margin	-0.84%	-6.59%	-8.09%	-2.60%	-0.08%	-14.85%	-2.98%	-2.05%	0.79%	-1.13%	-3.54%
Profit (Net Income) Margin	0.79%	-6.95%	-8.11%	-2.07%	-0.38%	-21.82%	-2.77%	-1.57%	1.51%	-5.53%	-4.42%
Tax Burden Percent	-715.84%	101.07%	100.51%	101.38%	-193.77%	138.12%	151.15%	112.32%	194.81%	-1,484.23%	102.66%
Interest Burden Percent	13.17%	104.25%	99.64%	78.55%	-242.15%	106.38%	61.50%	68.37%	98.59%	-32.84%	121.58%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	-4.27%	0.00%	0.00%	0.00%	-21.47%	15.01%	0.00%
Return on Invested Capital (ROIC)	-25.94%	-201.83%	-131.47%	-34.07%	-7.60%	-305.03%	-40.83%	-28.55%	0.76%	-23.58%	-35.79%
ROIC Less NNEP Spread (ROIC-NNEP)	-33.57%	-194.60%	-126.09%	-34.00%	-7.85%	-288.46%	-40.28%	-29.02%	-0.99%	-18.76%	-34.76%
Return on Net Nonoperating Assets (RNNOA)	20.40%	143.29%	78.30%	20.13%	5.20%	236.21%	29.83%	21.55%	0.80%	17.05%	30.81%
Return on Equity (ROE)	-5.53%	-58.54%	-53.16%	-13.93%	-2.40%	-68.82%	-11.00%	-7.00%	1.56%	-6.54%	-4.98%
Cash Return on Invested Capital (CROIC)	-34.93%	-71.38%	-43.08%	-47.83%	-57.11%	-162.71%	-87.39%	-77.97%	-93.77%	-101.01%	-137.77%
Operating Return on Assets (OROA)	-2.36%	-23.00%	-20.73%	-6.07%	-0.17%	-37.29%	-6.15%	-3.75%	1.35%	-1.65%	-3.02%
Return on Assets (ROA)	2.23%	-24.24%	-20.76%	-4.84%	-0.82%	-54.80%	-5.72%	-2.88%	2.59%	-8.04%	-3.77%
Return on Common Equity (ROCE)	-5.54%	-58.58%	-53.19%	-13.95%	-2.40%	-68.88%	-11.01%	-7.00%	1.56%	-6.54%	-4.99%
Return on Equity Simple (ROE_SIMPLE)	-48.37%	0.00%	-66.94%	-44.14%	-41.32%	0.00%	-10.19%	-10.01%	-8.50%	0.00%	-9.86%
Net Operating Profit after Tax (NOPAT)	-15	-76	-93	-30	-7.48	-115	-28	-20	0.51	-9.86	-21
NOPAT Margin	-1.01%	-4.97%	-6.44%	-2.05%	-0.47%	-10.89%	-2.42%	-1.90%	0.05%	-0.96%	-2.97%
Net Nonoperating Expense Percent (NNEP)	7.64%	-7.23%	-5.38%	-0.07%	0.25%	-16.57%	-0.55%	0.47%	1.76%	-4.82%	-1.03%
Return On Investment Capital (ROIC_SIMPLE)	-2.89%	-14.96%	-	-	-	-16.59%	-	-	-	-0.91%	-
Cost of Revenue to Revenue	96.69%	202.96%	104.42%	97.83%	0.00%	-200.23%	96.76%	94.90%	0.00%	157.14%	96.27%
SG&A Expenses to Revenue	4.30%	3.92%	4.35%	4.69%	4.76%	6.13%	6.34%	7.41%	6.62%	6.26%	7.48%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	4.75%	-95.86%	4.78%	5.09%	100.45%	315.79%	6.70%	7.81%	99.96%	-115.72%	7.98%
Earnings before Interest and Taxes (EBIT)	-13	-100	-117	-39	-1.29	-157	-34	-22	8.31	-12	-25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-5.97	-94	-111	-33	4.56	-152	-29	-16	12	-7.69	-21
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.57	1.66	2.81	3.98	3.59	7.70	8.26	8.17	9.06	6.38	8.86
Price to Tangible Book Value (P/TBV)	4.38	2.09	3.39	4.66	4.18	8.88	10.04	9.94	10.58	6.52	9.78
Price to Revenue (P/Rev)	0.30	0.13	0.29	0.51	0.51	1.18	1.68	1.87	2.85	2.78	6.35
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	8.72	4.11	5.93	7.62	6.96	23.37	19.78	20.12	30.37	52.76	51.01
Enterprise Value to Revenue (EV/Rev)	0.24	0.07	0.22	0.44	0.43	1.07	1.56	1.73	2.62	2.43	5.75
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.07	0.07	0.06	0.05	0.05	0.05	0.05	0.05	0.04	0.04	0.04
Long-Term Debt to Equity	0.00	0.07	0.06	0.04	0.04	0.05	0.04	0.04	0.03	0.04	0.04
Financial Leverage	-0.61	-0.74	-0.62	-0.59	-0.66	-0.82	-0.74	-0.74	-0.80	-0.91	-0.89
Leverage Ratio	3.57	3.07	3.02	2.90	2.53	2.02	2.12	2.11	1.84	1.54	1.61
Compound Leverage Factor	0.47	3.20	3.01	2.28	-6.14	2.15	1.30	1.45	1.81	-0.51	1.95
Debt to Total Capital	6.53%	6.90%	5.72%	5.07%	5.14%	4.66%	4.36%	4.46%	3.76%	4.01%	3.96%
Short-Term Debt to Total Capital	6.53%	0.00%	0.00%	1.23%	1.03%	0.00%	0.55%	0.54%	0.44%	0.46%	0.44%
Long-Term Debt to Total Capital	0.00%	6.90%	5.72%	3.84%	4.11%	4.66%	3.82%	3.91%	3.31%	3.55%	3.51%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	-0.11%	-0.11%	-0.12%	-0.08%	-0.08%	-0.06%	-0.06%	-0.05%
Common Equity to Total Capital	93.47%	93.10%	94.28%	95.04%	94.96%	95.46%	95.72%	95.62%	96.30%	96.05%	96.09%
Debt to EBITDA	-0.14	-0.15	-0.12	-0.17	-0.19	-0.18	-0.66	-0.78	-0.90	-0.52	-0.42
Net Debt to EBITDA	1.37	1.59	1.25	1.79	2.02	2.51	8.84	10.44	16.64	10.16	8.59
Long-Term Debt to EBITDA	0.00	-0.15	-0.12	-0.13	-0.16	-0.18	-0.57	-0.68	-0.79	-0.46	-0.37
Debt to NOPAT	-0.16	-0.17	-0.14	-0.20	-0.22	-0.20	-0.72	-0.84	-0.98	-0.59	-0.53
Net Debt to NOPAT	1.55	1.81	1.49	2.09	2.32	2.85	9.62	11.26	18.15	11.45	10.89
Long-Term Debt to NOPAT	0.00	-0.17	-0.14	-0.15	-0.18	-0.20	-0.63	-0.74	-0.86	-0.52	-0.47
Altman Z-Score	2.85	2.61	2.37	2.86	2.47	4.29	4.57	4.25	6.83	7.23	7.99
Noncontrolling Interest Sharing Ratio	-0.07%	-0.07%	-0.05%	-0.10%	-0.08%	-0.08%	-0.07%	-0.06%	-0.05%	-0.04%	-0.04%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.20	1.27	1.29	1.36	1.33	1.51	1.50	1.50	1.93	2.71	2.48
Quick Ratio	1.17	1.23	1.25	1.33	1.30	1.46	1.47	1.47	1.87	2.56	2.43
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	118	22	32	-4.13	-10	-203	-194	-170	-160	-35	-110
Operating Cash Flow to CapEx	-831.05%	502.73%	-217.97%	-565.13%	-1,522.01%	-1,555.60%	-318.52%	-517.93%	-1,636.02%	-1,431.90%	77.10%
Free Cash Flow to Firm to Interest Expense	77.90	14.17	19.92	-2.43	-7.94	-101.99	-119.82	-109.61	-107.03	-20.78	-110.22
Operating Cash Flow to Interest Expense	-21.11	10.43	-4.75	-11.03	-37.21	-30.69	-8.05	-13.64	-40.73	-29.95	2.65
Operating Cash Flow Less CapEx to Interest Expense	-23.65	8.36	-6.93	-12.98	-39.65	-32.66	-10.58	-16.27	-43.22	-32.04	-0.79
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	2.82	3.49	2.56	2.34	2.17	2.51	2.07	1.83	1.71	1.45	0.85
Accounts Receivable Turnover	4.26	6.19	4.12	3.70	3.78	6.02	4.32	3.79	4.37	6.08	3.09
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	215.33	217.44	205.68	202.19	195.95	181.69	194.07	191.05	198.66	164.15	124.24
Accounts Payable Turnover	25.08	26.34	3.34	1.62	0.00	0.00	6.38	5.07	0.00	15.68	6.22
Days Sales Outstanding (DSO)	85.65	59.01	88.54	98.65	96.61	60.67	84.50	96.19	83.59	60.05	118.02
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	14.55	13.86	109.15	225.47	0.00	0.00	57.18	71.93	0.00	23.27	58.72
Cash Conversion Cycle (CCC)	71.10	45.15	-20.61	-126.82	96.61	60.67	27.32	24.26	83.59	36.77	59.30
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	166	100	211	304	300	198	337	330	297	110	171
Invested Capital Turnover	25.69	40.61	20.41	16.65	16.30	28.01	16.87	15.06	15.86	24.48	12.04
Increase / (Decrease) in Invested Capital	-133	-98	-126	-26	2.71	88	166	150	160	25	90
Enterprise Value (EV)	1,451	412	1,253	2,317	2,087	4,632	6,666	6,643	9,026	5,802	8,709
Market Capitalization	1,785	783	1,617	2,690	2,477	5,096	7,201	7,193	9,812	6,647	9,624
Book Value per Share	$1.21	$1.14	$1.40	$1.65	$1.69	$1.63	$2.15	$2.12	$2.62	$2.53	$2.64
Tangible Book Value per Share	$0.99	$0.91	$1.16	$1.40	$1.45	$1.41	$1.77	$1.74	$2.25	$2.48	$2.39
Total Capital	535	506	610	712	726	693	911	920	1,124	1,084	1,130
Total Debt	35	35	35	36	37	32	40	41	42	43	45
Total Long-Term Debt	0.00	35	35	27	30	32	35	36	37	38	40
Net Debt	-334	-371	-364	-372	-389	-463	-535	-549	-785	-844	-915
Capital Expenditures (CapEx)	3.85	3.27	3.53	3.31	3.14	3.93	4.09	4.09	3.72	3.49	3.43
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-58	-100	4.05	97	92	7.82	86	97	82	33	22
Debt-free Net Working Capital (DFNWC)	311	306	403	505	518	503	660	687	909	921	981
Net Working Capital (NWC)	276	306	403	497	510	503	655	682	904	916	976
Net Nonoperating Expense (NNE)	-28	30	24	0.32	-1.45	115	3.98	-3.47	-15	47	10
Net Nonoperating Obligations (NNO)	-334	-371	-364	-372	-389	-463	-535	-549	-785	-931	-915
Total Depreciation and Amortization (D&A)	6.88	6.49	6.22	5.91	5.84	5.15	5.31	5.52	4.19	3.91	3.45
Debt-free, Cash-free Net Working Capital to Revenue	-0.97%	-1.65%	0.07%	1.85%	1.89%	0.18%	2.01%	2.53%	2.38%	1.40%	1.44%
Debt-free Net Working Capital to Revenue	5.19%	5.05%	7.20%	9.57%	10.64%	11.65%	15.42%	17.90%	26.40%	38.57%	64.72%
Net Working Capital to Revenue	4.61%	5.05%	7.20%	9.41%	10.48%	11.65%	15.30%	17.77%	26.25%	38.36%	64.39%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	412.94M	410.97M	411.59M	411.27M	408.94M	408.92M	405.79M	410.34M	413.14M	408.15M	411.07M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	412.94M	410.97M	411.59M	411.27M	413.44M	408.92M	405.79M	410.34M	426.59M	408.15M	411.07M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	413.95M	412.30M	412.02M	411.48M	411.26M	409.54M	406.04M	405.48M	414.83M	413.12M	411.85M
Normalized Net Operating Profit after Tax (NOPAT)	-15	-76	-93	-30	-5.02	-115	-28	-20	0.29	-9.86	-21
Normalized NOPAT Margin	-1.01%	-4.97%	-6.44%	-2.05%	-0.31%	-10.89%	-2.42%	-1.90%	0.03%	-0.96%	-2.97%
Pre Tax Income Margin	-0.11%	-6.88%	-8.07%	-2.04%	0.19%	-15.80%	-1.83%	-1.40%	0.78%	0.37%	-4.31%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-8.48	-63.79	-72.41	-22.69	-1.00	-78.71	-20.95	-14.06	5.57	-6.96	-24.63
NOPAT to Interest Expense	-10.22	-48.08	-57.62	-17.88	-5.83	-57.71	-17.01	-13.04	0.34	-5.91	-20.66
EBIT Less CapEx to Interest Expense	-11.02	-65.86	-74.59	-24.64	-3.45	-80.68	-23.47	-16.70	3.08	-9.05	-28.06
NOPAT Less CapEx to Interest Expense	-12.76	-50.15	-59.80	-19.83	-8.27	-59.68	-19.54	-15.67	-2.15	-8.00	-24.10
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-76.10%	-225.05%	-226.95%	0.00%	0.00%	9.27%

Frequently Asked Questions About agilon health's Financials

When does agilon health's financial year end?

According to the most recent income statement we have on file, agilon health's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has agilon health's net income changed over the last 5 years?

agilon health's net income appears to be on an upward trend, with a most recent value of -$260.10 million in 2024, falling from -$282.74 million in 2019. The previous period was -$262.80 million in 2023. Find out what analysts predict for agilon health in the coming months.

What is agilon health's operating income?

agilon health's total operating income in 2024 was -$292.13 million, based on the following breakdown:

Total Gross Profit: $4.84 million
Total Operating Expenses: $296.97 million

How has agilon health revenue changed over the last 5 years?

Over the last 5 years, agilon health's total revenue changed from $794.41 million in 2019 to $6.06 billion in 2024, a change of 662.9%.

How much debt does agilon health have?

agilon health's total liabilities were at $1.26 billion at the end of 2024, a 17.0% increase from 2023, and a 199.6% increase since 2020.

How much cash does agilon health have?

In the past 4 years, agilon health's cash and equivalents has ranged from $106.80 million in 2020 to $1.04 billion in 2021, and is currently $188.23 million as of their latest financial filing in 2024.

How has agilon health's book value per share changed over the last 5 years?

Over the last 5 years, agilon health's book value per share changed from 0.00 in 2019 to 1.14 in 2024, a change of 114.3%.

Related Companies

This page (NYSE:AGL) was last updated on 5/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

agilon health (AGL) Financials

Frequently Asked Questions About agilon health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

agilon health (AGL) Financials

Annual Income Statements for agilon health

Quarterly Income Statements for agilon health

Annual Cash Flow Statements for agilon health

Quarterly Cash Flow Statements for agilon health

Annual Balance Sheets for agilon health

Quarterly Balance Sheets for agilon health

Annual Metrics And Ratios for agilon health

Quarterly Metrics And Ratios for agilon health

Frequently Asked Questions About agilon health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools